FWIW, and we know it, the outcome will be decided in the best interests of business and not public health.
What is worthwhile noting is the likes of Bloomsberg reporting a shift in focus from the head of the FDA (clearly on the back of the rampant growth of ecigs).
With 25% annual growth and Big T buying up ecig companies the shift has pissed off the likes of Glantz. Anything that moves vaping further away from medicalisation has to be a good thing and with the head of the FDA saying a rethink is needed on nicotine plays right into our court - because I can't see us acting harsher on vaping than the US.